TBIO logo

Telesis Bio (TBIO) Stock

Profile

Sector:

Healthcare

Industry:

Medical Devices

Country:

United States

IPO:

18 June 2021

Indexes:

Not included

Website:

http://telesisbio.com

Description:

Telesis Bio (TBIO) is a biotechnology company that focuses on developing innovative tools for DNA synthesis and genetic engineering. They provide advanced solutions for researchers and companies in the life sciences field, helping to accelerate discoveries in medicine, agriculture, and other areas.

Key Details

Price

$0.60

Market Cap

$45.35 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$27.51 M(+0.27% YoY)

Annual EPS

-$29.52(+0.61% YoY)

PE Ratio

-

Annual ROE

-161.57%

Annual Debt To Equity

1.16

Beta

2.72

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 09, 2024

Analyst ratings

Recent major analysts updates

11 Aug '23 Keybanc
Sector Weight
09 Nov '22 Keybanc
Overweight
28 Mar '22 Keybanc
Overweight
13 July '21 Keybanc
Overweight
13 July '21 Jefferies
Buy
13 July '21 Cowen & Co.
Outperform

Screeners with TBIO included

Small cap stocks
NASDAQ earnings calendar
Stocks with high beta
Stocks below SMA 200
Stocks cheaper than 1 dollar
Stocks with low RSI
Most recommended stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.60
TBIO price is $0.60

Price YTD Change

-91.65%
TBIO price is down -91.65% since January 1st

Price All-time High

$396.00
TBIO price is currently -99.85% below its historical high of $396.00

Market Cap

$45.35 M
TBIO market capitalization is $45.35 million

Beta

2.72
TBIO beta is 2.72

200-day SMA

$4.47
TBIO 200-day simple moving average is currently -86.59% below its 200-day simple moving average

14-day RSI

25.52
TBIO 14-day relative strength index is 25.52

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

-80.18%
TBIO annual revenue is down -80.18% over the past 3 years

Annual Revenue Estimate

$9.20 M
TBIO annual revenue is currently +199.01% higher than the consensus analysts' forecast

Annual Net Income 3-Year Change

+11.27%
TBIO annual net profit is up +11.27% over the past 3 years

Annual EPS 3-Year Change

-3590%
TBIO annual earnings per share is down -3590% over the past 3 years

Annual EPS Estimate

-$24.95
TBIO annual earnings per share is currently +18.32% higher than the consensus analysts' forecast

Annual Gross Profit

$16.95 M
TBIO annual gross profit is $16.95 million

Annual Operating Profit

-$35.15 M
TBIO annual operaing income is -$35.15 million

Annual Operating Profit 3-Year Change

-421.51%
TBIO annual operaing income is down -421.51% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Gross Margin Sector Rank

57.57%
TBIO annual gross profit margin is higher than 57.57% of companies in Healthcare sector

Annual Operating Margin Sector Rank

40.86%
TBIO annual operating profit margin is higher than 40.86% of companies in Healthcare sector

Annual ROE

-161.57%
TBIO annual return on equity is -161.57%

Annual ROA

-67.78%
TBIO annual return on assets is -67.78%

Annual EBIT

-$44.59 M
TBIO annual earnings before interest & taxes is -$44.59 million

Annual EBITDA

-$29.43 M
TBIO annual earnings before interest, taxes, depreciation & amortization is -$29.43 million

Annual Interest Coverage Ratio

-14.36
TBIO annual interest coverage ratio is -14.36

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

7.6%
TBIO price to book ratio is higher than 7.6% of companies in Healthcare sector

PS Ratio Sector Rank

42.73%
TBIO price to sales ratio is higher than 42.73% of companies in Healthcare sector

Enterprise Value

$74.51 M
TBIO enterprise value is $74.51 million

Enterprise Value 1-Year Change

-87.94%
TBIO enterprise value is down -87.94% year-on-year

EV/EBITDA

-2.59
TBIO EV/EBITDA is -2.59

EV/EBITDA Sector Rank

34.39%
TBIO EV/EBITDA is higher than 34.39% of companies in Healthcare sector

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

89.83%
TBIO annual debt to equity ratio is higher than 89.83% of companies in Healthcare sector

Annual Quick Ratio

3.22
TBIO annual quick ratio is 3.22

Annual Quick Ratio Sector Rank

66.25%
TBIO annual quick ratio is higher than 66.25% of companies in Healthcare sector

Annual Current Ratio

3.71
TBIO annual current ratio is 3.71

Annual Current Ratio Sector Rank

54.29%
TBIO annual current ratio is higher than 54.29% of companies in Healthcare sector

Annual Total Assets

$70.41 M
TBIO annual total assets is $70.41 million

Annual Current Assets

$30.35 M
TBIO annual total current assets is $30.35 million

Annual Total Liabilities

$40.87 M
TBIO annual total liabilities is $40.87 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CAPEX

$1.98 M
TBIO annual capital expenditures is $1.98 million

Annual FCF

-$36.65 M
TBIO annual free cash flow is -$36.65 million

Annual FCF 3-Year Change

-115.94%
TBIO annual free cash flow is down -115.94% over the past 3 years

Institutional Ownership

Similar stocks

ICAD logo
iCAD (ICAD)
RPID logo
Rapid Micro Biosystems (RPID)
AFMD logo
Affimed NV (AFMD)
VYNE logo
VYNE Therapeutics (VYNE)
CalciMedica (CALC)
DXR logo
Daxor (DXR)
ACHL logo
Achilles Therapeutics (ACHL)
SHLT logo
SHL Telemedicine (SHLT)
RAPT logo
RAPT Therapeutics (RAPT)
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
TBIO
InvestorPlace23 February 2024

Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with some 7.4 million shares changing hands as of this writing.

Telesis Bio to Present at Jefferies Healthcare Conference 2023
Telesis Bio to Present at Jefferies Healthcare Conference 2023
Telesis Bio to Present at Jefferies Healthcare Conference 2023
TBIO
GlobeNewsWire08 June 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.

Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
TBIO
GlobeNewsWire06 June 2023

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery

Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
TBIO
Zacks Investment Research11 May 2023

Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.

Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
TBIO
Seeking Alpha25 March 2023

Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].

FAQ

  • What is the primary business of Telesis Bio?
  • What is the ticker symbol for Telesis Bio?
  • Does Telesis Bio pay dividends?
  • What sector is Telesis Bio in?
  • What industry is Telesis Bio in?
  • What country is Telesis Bio based in?
  • When did Telesis Bio go public?
  • Is Telesis Bio in the S&P 500?
  • Is Telesis Bio in the NASDAQ 100?
  • Is Telesis Bio in the Dow Jones?
  • When does Telesis Bio report earnings?
  • Should I buy Telesis Bio stock now?

What is the primary business of Telesis Bio?

Telesis Bio (TBIO) is a biotechnology company that focuses on developing innovative tools for DNA synthesis and genetic engineering. They provide advanced solutions for researchers and companies in the life sciences field, helping to accelerate discoveries in medicine, agriculture, and other areas.

What is the ticker symbol for Telesis Bio?

The ticker symbol for Telesis Bio is NASDAQ:TBIO

Does Telesis Bio pay dividends?

No, Telesis Bio does not pay dividends

What sector is Telesis Bio in?

Telesis Bio is in the Healthcare sector

What industry is Telesis Bio in?

Telesis Bio is in the Medical Devices industry

What country is Telesis Bio based in?

Telesis Bio is headquartered in United States

When did Telesis Bio go public?

Telesis Bio's initial public offering (IPO) was on 18 June 2021

Is Telesis Bio in the S&P 500?

No, Telesis Bio is not included in the S&P 500 index

Is Telesis Bio in the NASDAQ 100?

No, Telesis Bio is not included in the NASDAQ 100 index

Is Telesis Bio in the Dow Jones?

No, Telesis Bio is not included in the Dow Jones index

When does Telesis Bio report earnings?

The date for Telesis Bio's next earnings report has not been announced yet

Should I buy Telesis Bio stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions